$13.14
0.050.38%
At Close: -
$13.14
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Sotera Health
SHCNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Sotera Health (NASDAQ:SHC) Stock, Analyst Ratings, Price Targets, Forecasts
Sotera Health Co has a consensus price target of $17.23 based on the ratings of 12 analysts. The high is $28 issued by Credit Suisse on March 2, 2022. The low is $8 issued by Goldman Sachs on November 23, 2022. The 3 most-recent analyst ratings were released by Piper Sandler, Barclays, and Citigroup on May 21, 2024, April 10, 2024, and April 3, 2024, respectively. With an average price target of $14.33 between Piper Sandler, Barclays, and Citigroup, there's an implied 9.08% upside for Sotera Health Co from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Barclays
Citigroup
Jefferies
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Sotera Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/21/2024 | Buy Now | -1.07% | Piper Sandler | Jason Bednar | → $13 | Initiates | → Neutral | Get Alert |
| 04/10/2024 | Buy Now | 6.54% | Barclays | Luke Sergott | $19 → $14 | Maintains | Overweight | Get Alert |
| 04/03/2024 | Buy Now | 21.77% | Citigroup | Patrick Donnelly | $18 → $16 | Upgrade | Neutral → Buy | Get Alert |
| 03/25/2024 | Buy Now | 17.96% | Jefferies | David Windley | $15 → $15.5 | Upgrade | Hold → Buy | Get Alert |
| 03/11/2024 | Buy Now | 52.21% | RBC Capital | Sean Dodge | → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 03/04/2024 | Buy Now | 52.21% | RBC Capital | Sean Dodge | → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 02/28/2024 | Buy Now | 44.6% | Barclays | Luke Sergott | $17 → $19 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | — | Keybanc | Brett Fishbin | — | Initiates | → Sector Weight | Get Alert |
| 01/25/2024 | Buy Now | 29.38% | Barclays | Luke Sergott | $15 → $17 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | 52.21% | RBC Capital | Sean Dodge | $22 → $20 | Maintains | Outperform | Get Alert |
| 11/02/2023 | Buy Now | 14.16% | Barclays | Luke Sergott | $20 → $15 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 67.43% | RBC Capital | Sean Dodge | $18 → $22 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 75.04% | Keybanc | Matthew Mishan | $24 → $23 | Maintains | Overweight | Get Alert |
| 06/26/2023 | Buy Now | 82.65% | Keybanc | Matthew Mishan | → $24 | Upgrade | Sector Weight → Overweight | Get Alert |
| 06/22/2023 | Buy Now | — | Keybanc | Matthew Mishan | — | Maintains | Sector Weight | Get Alert |
| 05/04/2023 | Buy Now | 36.99% | RBC Capital | Sean Dodge | $19 → $18 | Maintains | Outperform | Get Alert |
| 05/04/2023 | Buy Now | 52.21% | Barclays | Luke Sergott | $21 → $20 | Maintains | Overweight | Get Alert |
| 04/04/2023 | Buy Now | 59.82% | Barclays | Luke Sergott | $22 → $21 | Maintains | Overweight | Get Alert |
| 03/01/2023 | Buy Now | 44.6% | RBC Capital | Sean Dodge | $8 → $19 | Maintains | Outperform | Get Alert |
| 01/23/2023 | Buy Now | 36.99% | JP Morgan | Casey Woodring | $6 → $18 | Upgrade | Underweight → Neutral | Get Alert |
| 01/11/2023 | Buy Now | 67.43% | Barclays | Luke Sergott | $6 → $22 | Upgrade | Underweight → Overweight | Get Alert |
| 01/11/2023 | Buy Now | 90.26% | Wolfe Research | Mike Polark | → $25 | Upgrade | Peer Perform → Outperform | Get Alert |
| 11/23/2022 | Buy Now | -39.12% | Goldman Sachs | Amit Hazan | $9 → $8 | Maintains | Neutral | Get Alert |
| 11/16/2022 | Buy Now | -54.34% | Barclays | Luke Sergott | $7 → $6 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 11/15/2022 | Buy Now | -54.34% | Barclays | Luke Sergott | $7 → $6 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 11/03/2022 | Buy Now | -54.34% | JP Morgan | Casey Woodring | $9 → $6 | Maintains | Underweight | Get Alert |
| 11/03/2022 | Buy Now | -39.12% | RBC Capital | Sean Dodge | $25 → $8 | Maintains | Outperform | Get Alert |
| 10/06/2022 | Buy Now | -39.12% | Barclays | Luke Sergott | $22 → $8 | Maintains | Equal-Weight | Get Alert |
| 10/05/2022 | Buy Now | -31.51% | Citigroup | Patrick Donnelly | → $9 | Downgrade | Buy → Neutral | Get Alert |
| 09/26/2022 | Buy Now | — | Keybanc | Matthew Mishan | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 09/21/2022 | Buy Now | -31.51% | JP Morgan | Tycho Peterson | $26 → $9 | Downgrade | Overweight → Underweight | Get Alert |
| 09/20/2022 | Buy Now | -31.51% | Goldman Sachs | Amit Hazan | $23 → $9 | Downgrade | Buy → Neutral | Get Alert |
| 07/13/2022 | Buy Now | 67.43% | Barclays | Luke Sergott | $24 → $22 | Maintains | Equal-Weight | Get Alert |
| 06/09/2022 | Buy Now | 97.87% | Wolfe Research | Mike Polark | → $26 | Downgrade | Outperform → Peer Perform | Get Alert |
| 04/06/2022 | Buy Now | 97.87% | Wolfe Research | Mike Polark | → $26 | Initiates | → Outperform | Get Alert |
| 03/21/2022 | Buy Now | 105.48% | Goldman Sachs | Amit Hazan | $31 → $27 | Maintains | Buy | Get Alert |
| 03/03/2022 | Buy Now | 67.43% | Jefferies | David Windley | $34 → $22 | Downgrade | Buy → Hold | Get Alert |
| 03/02/2022 | Buy Now | 113.09% | Credit Suisse | Matt Miksic | $31 → $28 | Maintains | Outperform | Get Alert |
| 03/02/2022 | Buy Now | 82.65% | Barclays | Luke Sergott | → $24 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/02/2022 | Buy Now | 128.31% | Keybanc | Matthew Mishan | $33 → $30 | Maintains | Overweight | Get Alert |
| 08/13/2021 | Buy Now | 143.53% | Barclays | Luke Sergott | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Sotera Health (SHC) stock?
The latest price target for Sotera Health (NASDAQ:SHC) was reported by Piper Sandler on May 21, 2024. The analyst firm set a price target for $13.00 expecting SHC to fall to within 12 months (a possible -1.07% downside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sotera Health (SHC)?
The latest analyst rating for Sotera Health (NASDAQ:SHC) was provided by Piper Sandler, and Sotera Health initiated their neutral rating.
When was the last upgrade for Sotera Health (SHC)?
The last upgrade for Sotera Health Co happened on April 3, 2024 when Citigroup raised their price target to $16. Citigroup previously had a neutral for Sotera Health Co.
When was the last downgrade for Sotera Health (SHC)?
The last downgrade for Sotera Health Co happened on November 16, 2022 when Barclays changed their price target from $7 to $6 for Sotera Health Co.
When is the next analyst rating going to be posted or updated for Sotera Health (SHC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sotera Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sotera Health was filed on May 21, 2024 so you should expect the next rating to be made available sometime around May 21, 2025.
Is the Analyst Rating Sotera Health (SHC) correct?
While ratings are subjective and will change, the latest Sotera Health (SHC) rating was a initiated with a price target of $0.00 to $13.00. The current price Sotera Health (SHC) is trading at is $13.14, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.